Saturskaya A.S.
The peculiarities of trimetazidine cardioprotective effect in experimental cardiosclerosis in rats with different degree of sensitivity to hypoxia
I.Ya. Horbachevsky Ternopil State Medical University, Ukraine
Abstract.
The article presents the results of an experimental study which investigates the peculiar changes of lipid peroxidation indices, conjugated dienes and malon-dialdehydes (MDA) in particular, caused by the use of trimetazidine in case of diffuse cardiosclerosis development in rats with different resistance to hypoxia. Researches were conducted on 192 white male rats which were divided into experimental groups on the basis of their different resistance to exogenous hypobaric hypoxia. The experimental model of diffuse ischemic necrotic cardiosclerosis (DINC) was simulated. For the correction of metabolic disorders on the DINC simulation, the aqueous suspension of trimetazidine (10 mg/kg) was administered intragastrally once a day during the whole period of observation. Experimentally it has been proved that, in case of diffuse ischemic necrotic cardiosclerosis development the concentration of lipid peroxidation products in the myocardium of rats receiving metabolic therapy with trimetazidine increases less rapidly than without this correction at all stages of the modelled pathology (7, 14, 30 days of DINC). It has been revealed that the most pronounced therapeutic effect is observed in animals with low resistance to hypoxia, slightly less pronounced – in animals with medium resistance to hypoxia, and the lowest one – in animals with high resistance to hypoxia. This pattern was observed at all stages of observation, but it was most clearly marked in the early period of cardiosclerotic process, indicating the feasibility of early use of metabolic therapy. It also explains the absence of cardioprotective effect of trimetazidine at the later stages of cardiosclerosis, when the myocardial fibrosis is already formed. Different efficacy of metabolic therapy on modelling cardiosclerotic process in animals with different resistance to hypoxia confirms antihypoxic and antioxidant effects of trimetazidine.
Key words: hypoxia, heart, lipid peroxidation, diffuse cardiosclerosis, trimetazidine.
References
1. Yusuf S, Rangarajan S, Teo K, Islam S, Li W, Liu L, Bo J, Lou Q, Lu F, Liu T, Yu L, Zhang S, Mony P, Swaminathan S, Mohan V, Gupta R, Kumar R, Vijayakumar K, Lear S, Anand S, Wielgosz A, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Yusoff K, Ismail N, Iqbal R, Rahman O, Rosengren A, Yusufali A, Kelishadi R, Kruger A, Puoane T, Szuba A, Chifamba J, Oguz A, McQueen M, McKee M, Dagenais G. Cardiovascular risk and events in 17 low-, middle-, and high-income countries. N Engl J Med. 2014 Aug 28;371(9):818-27.
2. Sutra T, Oiry C, Azay-Milhau J, Youl E, Magous R, Teissèdre PL, Cristol JP, Cros G. Preventive effects of nutritional doses of polyphenolic molecules on cardiac fibrosis associated with metabolic syndrome: involvement of osteopontin and oxidative stress. J Agric Food Chem. 2008 Dec;56(24):11683-7.
3. Moibenko AA, Dosenko VE, Parkhomenko AN. Endogennye mekhanizmy kardioprotektsii kak osnova patogeneticheskoi terapii zabolevanii serdtsa [Endogenic mechanisms of a cardiopatronage as basis of pathogenetic therapy of diseases of heart]. Kiev, Ukraina: Naukova dumka; 2008. 518 р.
4. Gupta R, Sawhney JP, Narain VS. Treatment of stable angina pectoris with trimetazidine modified release in Indian primary-care practice. Am J Cardiovasc Drugs. 2005;5(5):325-9.
5. Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis. 2003 Apr;14(2):171-9.
6. Khara MR, Bodnar YaYa, Saturskaya AS, Pelykh VE; zaiavitel' i patentoobladatel' Ternopol'skii gos. med. un-t im. I. Ia. Gorbachevskogo. Sposob modelirovaniia diffuznogo kardioskleroza [Way of modeling of a diffuse cardiosclerosis]: pat. 66297 Ukraina: MPK G 09 B 23/28. № u201108088; zaiavl. 29.06.11; opubl. 26.12.11, Biul. № 24.
7. Merkulov GA. Kurs patogistologicheskoi tekhniki [Course of patogistologichesky equipment]. Leningrad, RF: Meditsina; 1969. 422 р.
8. Danchenko OP, Pentiuk OO. Vpliv trimetazidinu, tіotriazolіnu, taurinu ta ubіkhіnonu na gіpokholesterinemіchnu dіiu simvastatinu u shchurіv z eksperimental'noiu gіperkholesterinemієiu [Effect of trimetazidine, Thiotriazoline, taurine and ubiquinone in the cholesterol-lowering effect of simvastatin in rats with experimental hypercholesterolemia]. Farmakologіia ta lіkars'ka toksikologіia. 2008;(5-6):63-8.
9. Korobeinikova EN. Modifikatsiia opredeleniia produktov POL v reaktsii s tiobarbiturovoi kislotoi [ Modification of the definition of lipid peroxidation products in the reaction with thiobarbituric acid]. Laboratornoe delo. 1989;(7):8–10.
10. Kamyshnikov VS, red. Metody klinicheskikh laboratornykh issledovanii [Methods of clinical laboratory trials]. 4-e izd. Moscow, RF: MEDpress-inform; 2011. 750 р.
11. Winter JL, Castro PF, Quintana JC, Altamirano R, Enriquez A, Verdejo HE, Jalil JE, Mellado R, Concepción R, Sepúlveda P, Rossel V, Sepúlveda L, Chiong M, García L, Lavandero S. Effects of trimetazidine in nonischemic heart failure: a randomized study. J Card Fail. 2014 Mar;20(3):149-54.
12. Mahfoudh-Boussaid A, Hadj Ayed Tka K, Zaouali MA, Roselló-Catafau J, Ben Abdennebi H. Effects of trimetazidine on the Akt/eNOS signaling pathway and oxidative stress in an in vivo rat model of renal ischemia-reperfusion. Ren Fail. 2014 Oct;36(9):1436-42.
13. Gao W, Li J. Femoral artery occlusion increases muscle pressor reflex and expression of hypoxia-inducible factor-1α in sensory neurons. J Cardiovasc Dis. 2013 Oct;1(2):34-40.
14. Niemi H, Honkonen K, Korpisalo P, Huusko J, Kansanen E, Merentie M, Rissanen TT, André H, Pereira T, Poellinger L, Alitalo K, Ylä-Herttuala S. HIF-1α and HIF-2α induce angiogenesis and improve muscle energy recovery. Eur J Clin Invest. 2014 Oct;44(10):989-99.
15. Dedkova EN, Seidlmayer LK, Blatter LA. Mitochondria-mediated cardioprotection by trimetazidine in rabbit heart failure. J Mol Cell Cardiol. 2013 Jun;59:41-54.
